Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis

NCT00598403 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 611

Last updated 2010-06-29

No results posted yet for this study

Summary

The main objective of the study is to comparatively assess the efficacy and tolerability of the drugs under study in the treatment of acute uncomplicated cystitis.

Conditions

Interventions

DRUG

cefditoren pivoxil

400 mg, oral, single dose during 3 days

DRUG

Ciprofloxacin

250 mg, oral, twice a day for 3 days

Sponsors & Collaborators

  • Tedec-Meiji Farma, S.A.

    lead INDUSTRY

Principal Investigators

  • Jose L Ballve

  • Josep R Toll

  • Rosa Viñas

  • Rosaura Figueras

  • Joan Palou

  • Gabriel Martín

  • Ramon Pons

  • Manel Terns

  • Josep L Fernandez

  • Pere Toran

  • Pilar Montero

  • Bingen Uriondo

  • Pablo Daza

  • Jesus Zorita

  • Ander Larrazabal

  • Natividad Gonzalez

  • Jose F Magdalena

  • Fernando Martin

  • Jose Porta

  • Mª Rosa Magallon

  • Mª Sol Reixa

  • Jesus Torrecilla

  • Isabel Blasco

  • Antonio Hidalgo

  • Alicia Alvarez

  • Gabriel Romera

  • Estrella Castro

  • Manuel M Ortega

  • Salvador Pertusa

  • Manuel Ramirez

  • Aggelos Pefanis

  • Chatzimouratidis

  • Jose V Vaquer

  • Nicolas Salvador

  • Jose L Pardo

  • Joaquin Aracil

  • Mª Jesus Barreda

  • Artemio Alvarez

  • Vicente Lopez

  • Panagiotis Gargalianos

  • Dolores M Maestre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-12-31
Completion
2010-06-30

Countries

  • Greece
  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00598403 on ClinicalTrials.gov